Strategic investor Ornim Medical has attracted a significant strategic investment from GE Healthcare, indicating strong credibility and potential co-development or channel opportunities that a sales team can leverage for larger hospital deployments and joint go-to-market initiatives.

Clinical differentiation The CerOx monitor provides simultaneous non-invasive measurement of blood flow and oxygen saturation, a unique capability that can help win long sales cycles by addressing comprehensive perfusion monitoring needs in critical care, neurology, and surgical settings.

Regulatory edge The existence of an FDA approved c-FLOW device reinforces credibility and may pave the path for faster approvals in additional markets, making it easier to position upgrades or bundled offerings to hospitals seeking compliant perfusion solutions.

RETAC opportunity With a small headcount and a broad distribution footprint implied by global patents, there is potential to partner with distributors or OEMs to scale reach in international markets, leveraging UTLight technology to target ICU, OR, and perioperative segments.

Cost of care impact The technology’s ability to inform perfusion decisions and potentially reduce patient care costs creates a compelling ROI narrative for hospital procurement teams, enabling sales conversations around value-based purchasing and cost-to-care savings.